Parabilis Medicines, Inc. Common Stock (PBLS) — Working Capital to Net Assets Ratio
Parabilis Medicines, Inc. Common Stock (PBLS) has a Working Capital to Net Assets ratio of 113.8% as of March 2026. Working capital of $277.83 Million (current assets of $332.07 Million minus current liabilities of $54.24 Million) is measured against net assets of $244.22 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Parabilis Medicines, Inc. Common Stock financial flexibility index to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Parabilis Medicines, Inc. Common Stock Working Capital to Net Assets (2024–2025)
This chart shows how Parabilis Medicines, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of March 2026, the ratio stands at 113.8%, reflecting working capital of $277.83 Million against net assets of $244.22 Million USD. See Parabilis Medicines, Inc. Common Stock (PBLS) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Parabilis Medicines, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Parabilis Medicines, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Parabilis Medicines, Inc. Common Stock (PBLS) total market value.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 166.0% | $-27.43 Million | $-16.52 Million | $29.36 Million | $56.79 Million | ▲ +60.1 pp |
| 2024 | 105.9% | $59.80 Million | $56.44 Million | $92.21 Million | $32.41 Million | — |